Saniona AB (publ) (LON:0RQJ)

Market Cap	125.68M -26.5%
Revenue (ttm)	33.02M +25.0%
Net Income	14.27M -14.4%
EPS	0.10 -28.3%
Shares Out	n/a
PE Ratio	9.26
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,000
Open	12.16
Previous Close	n/a
Day's Range	12.09 - 12.16
52-Week Range	8.66 - 28.15
Beta	1.16
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 26, 2026

About Saniona AB

Saniona AB (publ), a clinical-stage biopharmaceutical company, focuses on discovering, developing, and delivering innovative treatments for neurological and psychiatric disorders in Ireland, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company’s product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy that has completed Phase 2 clinical trial for the trea...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 44
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RQJ

Financial Performance

In 2025, Saniona AB's revenue was 434.40 million, an increase of 29.80% compared to the previous year's 334.67 million. Earnings were 284.67 million, an increase of 50.85%.

Financial numbers in SEK

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 10, 2026

Data Sources Report a data error